| Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B. | |
| | |
MedLine Citation:
|
PMID: 21291689 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
OBJECTIVE: Our objective was to develop a simple algorithm that could be applied in routine clinical practice to diagnose type III hyperlipoproteinemia based on plasma total cholesterol, triglyceride and apolipoprotein (Apo) B. METHODS: Analysis of plasma lipid, lipoprotein lipid, and apolipoprotein data from 1771 patients in a tertiary care lipid clinic, from whom all data had been collected prospectively by standardized methods. Of the 1771, based on the Fredrickson classification, 16 had type I hyperlipoproteinemia, 736 type IIa hyperlipoproteinemia, 371 type IIb hyperlipoproteinemia, 38 type III hyperlipoproteinemia, 509 type IV hyperlipoproteinemia, and 101 type V hyperlipoproteinemia. RESULTS: Mean plasma ApoB was highest in type IIb (1.53 ± 0.36 g/L), borderline high (1.1 ± 0.23 g/L) in type IV, normal in type III and type V (1.04 ± 0.21 g/L and 0.96 ± 0.40 g/L, respectively) and low in type I (0.48 ± 0.16 g/L). In type III hyperlipoproteinemia, very low-density lipoprotein ApoB (ie, d<1.006 g/mL) accounted for 42.3% of total ApoB, a value that was substantially higher than in any of the other dyslipoproteinemias. The total cholesterol (TC)/ApoB ratio was similar in the uncommon dyslipoproteinemias-type I, III, and V hyperlipoproteinemia (10.5 ± 4.8, 8.7 ± 1.8, 10.3 ± 7.7, respectively)-and much higher than in the common dyslipoproteinemias-type IIa, IIb, and type IV hyperlipoproteinemia (5.0 ± 0.4, 4.6 ± 0.4, 4.9 ± 1.1, respectively). Notwithstanding that the TC/ApoB area under the curve-receiver operating characteristic (AUC-ROC) was very high (0.93), it did not discriminate among the uncommon dyslipoproteinemias. However, the triglyceride (TG)/ApoB ratio was much higher in type I (42.4 ± 28.8) and type V (25.6 ± 30.2) than in type III (5.8 ± 3.2). All cases of type III had a TC/ApoB ratio >6.2 and a TG/ApoB ratio of <10.0. Using these cutpoints, there were also no false positives. Based on the TC/ApoB ratio and the TG/ApoB ratio, the AUC-ROC was 0.99. CONCLUSIONS: These data indicate that type III hyperlipoproteinemia can be reliably diagnosed based on plasma cholesterol, TG, and ApoB. |
| | |
Authors:
|
Allan Sniderman; Andre Tremblay; Jean Bergeron; Claude Gagné; Patrick Couture |
Related Documents
:
|
22595329 - Protective effects of yacon (smallanthus sonchifolius) intake on experimental colon car... 2049519 - Gating current kinetics in myxicola giant axons. order of the back transition rate cons... 8506789 - The effects of calories and taste on habituation of the human salivary response. 12034399 - Argon ion beam hemostasis with albumin after liver resection. 12078699 - Cloud physics lidar: instrument description and initial measurement results. 15682509 - Symmetry properties of tetraammine platinum(ii) with c2v and c4v point groups. 8471409 - Food intake increases the relative oral bioavailability of vanoxerine. 16229399 - Nutritional intervention improves the caloric and proteic ingestion of head and neck ca... 3408219 - More exercise for the hyperlipidaemic patients? |
Publication Detail:
|
Type: Journal Article Date: 2007-07-27 |
Journal Detail:
|
Title: Journal of clinical lipidology Volume: 1 ISSN: 1933-2874 ISO Abbreviation: J Clin Lipidol Publication Date: 2007 Aug |
Date Detail:
|
Created Date: 2011-02-04 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101300157 Medline TA: J Clin Lipidol Country: United States |
Other Details:
|
Languages: eng Pagination: 256-63 Citation Subset: - |
Affiliation:
|
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, H7.22, Royal Victoria Hospital, MUHC, 687 Pine Avenue West, Montreal, Quebec, Canada H3A 1A1. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Revisiting niacin: reviewing the evidence.
Next Document: Efficacy and tolerability of fixed-dose combination of simvastatin plus ezetimibe in patients with p...